Search
Returning search results with filters:
Remove filter for
Issue: New safety information
Remove filter for
Issue: COVID
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 7 of 7 items.
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26
Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant
AlertHealth professional risk communication | 2022-04-14
Rapid antigen test kits and potential exposure to hazardous substances
AlertPublic advisory | 2022-02-24
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
AlertHealth professional risk communication | 2022-01-17
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
AlertHealth professional risk communication | 2022-01-07
Importation of COVID-19 Vaccine Moderna with up to 15 Doses per Vial and English-only Vial and Carton Labels (US-Labelled Supply)
AlertHealth professional risk communication | 2021-06-14